OR
ORGO.US Organogenesis Holdings Inc
- Market cap
- USD 104M
- P/E
- -
- P/B
- 0.88x
- ROE
- -206.1%
- Dividend yield
- 10.91%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ORGO.US undervalued?
Graham numberThe Graham number of Organogenesis Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Organogenesis Holdings Inc fundamental analysis
No fundamental analysis for Organogenesis Holdings Inc yet.
Organogenesis Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin subs…
Full company profileOrganogenesis Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Organogenesis Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 193M | 261M | 338M | 467M | 451M | 433M | 482M | 563M | 169M |
| Gross Profit | -209K | -4.59M | 125M | 185M | 251M | 353M | 346M | 327M | 366M | 426M | 57.0M |
| Operating Income | 209K | -4.59M | -51.6M | -29.9M | 26.7M | 72.2M | 22.3M | 12.5M | -1.28M | 55.9M | -194M |
| EBITDA | 7.11M | -4.59M | -46.9M | -19.7M | 37.2M | 87.0M | 40.3M | 36.0M | 15.8M | 73.9M | -167M |
| Net Income | -209K | -2.09M | -64.8M | -38.7M | 17.2M | 94.2M | 15.5M | 4.95M | 861K | 37.0M | -247M |
| EPS | -0.02 | -0.03 | -0.94 | -0.42 | 0.15 | 0.70 | 0.12 | 0.04 | 0.01 | 0.28 | -1.91 |
| Balance Sheet | |||||||||||
| Total Assets | 311M | 313M | 164M | 221M | 290M | 443M | 449M | 460M | 498M | 599M | 369M |
| Total Liabilities | 11.3M | 14.8M | 117M | 165M | 148M | 202M | 184M | 181M | 113M | 165M | 106M |
| Shareholders' Equity | 300M | 298M | 47.0M | 55.6M | 142M | 241M | 266M | 279M | 385M | 434M | 120M |
| Cash & Short-term Investments | 1.04M | 126K | 21.3M | 60.2M | 84.4M | 114M | 102M | 104M | 136M | 93.7M | 21.3M |
| Total Debt | - | 17.9M | 59.3M | 101M | 84.8M | 132M | 124M | 119M | 43.3M | 133M | 64.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -562K | -587K | -60.7M | -33.5M | 5.47M | 62.0M | 24.9M | 30.9M | 14.2M | -10.3M | -38.8M |
| Capital Expenditure | 1.36M | 2.43M | 1.86M | 6.23M | 17.7M | 31.2M | 33.9M | 24.4M | 10.0M | 14.2M | 7.62M |
| Free Cash Flow | -1.92M | -3.01M | -62.6M | -39.8M | -12.2M | 30.8M | -9.04M | 6.55M | 4.18M | -24.5M | -46.4M |
| Ratios | |||||||||||
| ROE | -0.1% | -0.7% | -137.8% | -69.6% | 12.2% | 39.0% | 5.8% | 1.8% | 0.2% | 8.5% | -206.1% |
| ROA | -0.1% | -0.7% | -39.6% | -17.5% | 5.9% | 21.3% | 3.5% | 1.1% | 0.2% | 6.2% | -66.9% |
| Net Profit Margin | - | - | -33.5% | -14.8% | 5.1% | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% | -146.4% |
| Debt to Equity | - | 0.06x | 1.26x | 1.81x | 0.60x | 0.55x | 0.47x | 0.43x | 0.11x | 0.31x | 0.54x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Organogenesis Holdings Inc dividends
- Dividend yield
- 10.91%
- Forward dividend
- -
- Payout ratio
- 30.7%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 11.4M | 0.09 | 30.7% |
| 2024 | USD 1.80M | 0.01 | 208.8% |
| 2023 | - | - | - |
| 2022 | USD 648K | 0.00 | 4.2% |
| 2021 | USD 1.46M | 0.01 | 1.6% |
| 2020 | - | - | - |
| 2019 | USD 57.9M | 0.62 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Organogenesis Holdings Inc
- Insiders 44.45%
- Institutions 50.79%
- Public & others 4.76%
- Shares outstanding 130M
- Free float 62.2M
Top funds holding ORGO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.99M | 1.53% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.76M | 1.36% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 655K | 0.50% | -13.19% | Aug 2026 |
| iShares Russell 2000 Value ETF | 629K | 0.48% | 0.00% | Oct 2026 |
| Vanguard Explorer Inv | 492K | 0.38% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap Value I | 469K | 0.36% | +64.74% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 401K | 0.31% | +0.24% | Oct 2026 |
| Vanguard Russell 2000 ETF | 400K | 0.31% | +1.03% | Sep 2026 |
| Fidelity Extended Market Index | 357K | 0.27% | +23.39% | Sep 2026 |
| DFA U.S. Targeted Value I | 356K | 0.27% | 0.00% | Sep 2026 |
| Vanguard Strategic Equity Inv | 334K | 0.26% | 0.00% | Sep 2026 |
| Dimensional US Small Cap Value ETF | 268K | 0.21% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 262K | 0.20% | 0.00% | Oct 2026 |
| DFA US Micro Cap I | 239K | 0.18% | 0.00% | Sep 2026 |
| Schwab Small-Cap Equity | 229K | 0.18% | -32.91% | Sep 2026 |
| Vanguard Health Care ETF | 221K | 0.17% | +0.10% | Sep 2026 |
| Dimensional US Targeted Value ETF | 221K | 0.17% | 0.00% | Oct 2026 |
| Voya MI Dynamic SMID Cap I | 213K | 0.16% | +9.65% | Sep 2026 |
| iShares Micro-Cap ETF | 208K | 0.16% | 0.00% | Oct 2026 |
| Dimensional US Core Equity 2 ETF | 205K | 0.16% | 0.00% | Oct 2026 |
Top institutions holding ORGO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Morgan Stanley - Brokerage Accounts | 11.7M | 9.03% | +0.90% | Jun 2026 |
| Soleus Capital Management, L.P. | 10.1M | 7.81% | +0.55% | Jun 2026 |
| BlackRock Inc | 7.25M | 5.59% | +47.96% | Jun 2026 |
| Assenagon Asset Management SA | 3.94M | 3.03% | +100.00% | Jun 2026 |
| AQR Capital Management LLC | 3.01M | 2.32% | +241.58% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.91M | 2.24% | +0.18% | Jun 2026 |
| D. E. Shaw & Co LP | 2.89M | 2.23% | +25.69% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.45M | 1.89% | -19.71% | Sep 2026 |
| Acadian Asset Management LLC | 1.97M | 1.52% | +27.80% | Sep 2026 |
| Geode Capital Management, LLC | 1.94M | 1.49% | +8.50% | Jun 2026 |
| Deutsche Bank AG | 1.71M | 1.31% | +0.03% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.61M | 1.24% | +10.95% | Jun 2026 |
| State Street Corp | 1.52M | 1.17% | -0.34% | Jun 2026 |
| Charles Schwab Investment Management Inc | 905K | 0.70% | +2.86% | Jun 2026 |
| The Goldman Sachs Group Inc | 887K | 0.68% | +70.54% | Jun 2026 |
| Renaissance Technologies Corp | 887K | 0.68% | -12.76% | Sep 2026 |
| Citadel Advisors Llc | 868K | 0.67% | +59.48% | Jun 2026 |
| FLAX POND CAPITAL, LLC | 843K | 0.65% | +100.60% | Jun 2026 |
| SG Americas Securities, LLC | 773K | 0.60% | -2.28% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 692K | 0.53% | 0.00% | Jun 2026 |
Organogenesis Holdings Inc company profile
- Company name
- Organogenesis Holdings Inc
- Ticker
- ORGO.US
- Exchange
- USA Stocks
- Listed since
- Jan 5, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 854
- Fiscal year end
- December
- Address
- 85 Dan Road, Canton, MA, United States, 02021
- Phone
- 781 575 0775
- Website
- organogenesis.com
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Organogenesis Holdings Inc management
8- Mr. Gary S. Gillheeney Sr.President, CEO, Chair of the Board · born 1955
- Mr. David C. FranciscoChief Financial Officer · born 1966
- Mr. Patrick BilboChief Operating Officer · born 1962
- Ms. Lori H. Freedman B.A., Esq., J.D.Chief Administrative & Legal Officer · born 1967
- Mr. Brian GrowChief Commercial Officer · born 1976
- Mr. Patrick McGuireChief Accounting Officer · born 1986
- Mr. Robert CavorsiChief Business Officer · born 1979
- Mr. William R. Kolb CPASecretary